Solving the degradation problem of continuous ceftazidime infusions-the Cooltaz study

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Clinical Pharmacy
• Pediatric Infectious Diseases

Background:

• Ceftazidime is a vital antibiotic for treating Pseudomonas aeruginosa infections, particularly in cystic fibrosis patients.
• Current treatment often involves intermittent infusions, limiting home-based care options.
• Instability and toxic pyridine byproduct formation in 24-hour infusions pose significant challenges for continuous home therapy.

Purpose of the Study:

• To identify an optimal temperature for stabilizing 24-hour ceftazidime infusions.
• To evaluate the effectiveness of simple temperature control methods in mitigating ceftazidime degradation and pyridine generation.
• To assess the feasibility of home-based, continuous 24-hour ceftazidime infusions.

Main Methods:

• In vitro experiments involved incubating ceftazidime infusions at 4°C, 25°C, and 33°C, with regular sampling for drug and pyridine quantification via HPLC.
• Simulated home infusion experiments involved children carrying insulated bags with ceftazidime infusers (2g, 6g, 12g) and varying numbers of ice packs for 24 hours.
• Drug and pyridine concentrations were analyzed to assess stability and byproduct formation under different temperature conditions.

Main Results:

• In vitro studies showed ceftazidime stability (>90%) at 4°C and 25°C, but degradation at 33°C (84%).
• Pyridine levels increased significantly over 24 hours, with marked increases at higher temperatures (550% at 25°C, 1040% at 33°C).
• Home infusion simulations demonstrated that controlled temperatures (17-25°C) with at least one ice pack maintained ceftazidime levels (>90%) and reduced pyridine production by 44-57%.

Conclusions:

• Utilizing an ice pack within an insulated bag effectively halves pyridine production during 24-hour ceftazidime infusions.
• Temperature-controlled continuous 24-hour intravenous ceftazidime infusions are a viable alternative to twice-daily 12-hour infusions.
• This approach facilitates convenient and safe home-based ceftazidime treatment for pediatric patients, improving quality of life.